Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financing: 2020 Ends On A High Note For Medtech

A look at financing activity across the medical device and in vitro diagnostics industries, October-December 2020

Executive Summary

During Q4, device company fundraising totaled $4.2bn; while in vitro diagnostic firms and research tools players raised $6.1bn.

You may also be interested in...



Medical Imaging Disruptor Nano-X Pushes On With Launch Plans In Face Of Shareholder Lawsuit

Nano-X Imaging is on a mission to disrupt the market for X-ray imaging equipment by offering a low-cost medical imaging service to untapped markets through a network of equipment dotted around the world. However, some shareholders are claiming the company mislead investors.

Deals In Depth: August 2022

The height of the summer saw eight $1bn plus deals penned, including those by Pfizer and Roche.

Deals In Depth: July 2022

Three $1B+ alliances were penned in July. Topping the list was a potential $2M deal between Skyhawk Therapeutics and Sanofi for the development of novel small molecules that modulate RNA splicing for challenging oncology and immunology targets. Skyhawk will grant Sanofi exclusive worldwide intellectual property rights to candidates discovered and developed under the collaboration. Skyhawk receives $54M up front and is also eligible to receive over $2B in potential milestone payments, as well as potential royalties on future sales. In the top July M&A by deal value, SD Biosensor and a consortium formed with private equity firm SJL Partners agreed to acquire US-based in vitro diagnostics company Meridian Bioscience in an all-cash transaction valued at approximately $1.53B. Founded in 1976, Meridian is a fully integrated life science company that manufactures, markets, and distributes a broad range of diagnostic test kits, purified reagents, and biopharmaceutical enabling technologies. The company has gained expertise through numerous acquisitions over the years including point-of-care testing firm Magellan Biosciences, GenePOC (develops POC molecular diagnostics for infectious diseases), and gastrointestinal diagnostics maker Exalenz Bioscience. Financing reached $3.97bn in biopharma, $851m in device, and $318m in diagnostics.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT143433

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel